J E Rubnitz1, A T Look. 1. Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.
Abstract
PURPOSE: This review summarizes the molecular genetics of childhood leukemias, with emphasis on pathogenesis and clinical applications. DESIGN: We first describe the most common genetic events that occur in pediatric acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). We then illustrate how these molecular alterations may be used to alter therapy. RESULTS: In childhood ALL, the TEL-AML1 fusion and hyperdiploidy are both associated with excellent treatment outcomes and therefore identify patients who may be candidates for less intensive therapy. In contrast, MLL gene rearrangements and the BCR-ABL fusion confer a poor prognosis; these patients may be best treated by allogeneic bone marrow transplantation in first remission. CONCLUSIONS: Although clinical features are important prognostic indicators, genetic alterations of leukemic blasts may be better predictors of outcome for acute leukemia patients. We therefore favor risk-adapted therapy based on classification schemes that incorporate both genetic and clinical features.
PURPOSE: This review summarizes the molecular genetics of childhood leukemias, with emphasis on pathogenesis and clinical applications. DESIGN: We first describe the most common genetic events that occur in pediatric acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). We then illustrate how these molecular alterations may be used to alter therapy. RESULTS: In childhood ALL, the TEL-AML1 fusion and hyperdiploidy are both associated with excellent treatment outcomes and therefore identify patients who may be candidates for less intensive therapy. In contrast, MLL gene rearrangements and the BCR-ABL fusion confer a poor prognosis; these patients may be best treated by allogeneic bone marrow transplantation in first remission. CONCLUSIONS: Although clinical features are important prognostic indicators, genetic alterations of leukemic blasts may be better predictors of outcome for acute leukemiapatients. We therefore favor risk-adapted therapy based on classification schemes that incorporate both genetic and clinical features.
Authors: L L Hjalgrim; H O Madsen; M Melbye; P Jørgensen; M Christiansen; M T Andersen; N Pallisgaard; P Hokland; N Clausen; L P Ryder; K Schmiegelow; H Hjalgrim Journal: Br J Cancer Date: 2002-10-21 Impact factor: 7.640
Authors: Abdallah Al-Nasser; Hassan El-Solh; Edward De Vol; Ibrahim El-Hassan; Ali Alzahrani; Reem Al-Sudairy; Mohammed Al-Mahr; Abdulrahman Al-Musa; Abdulla Al-Jefri; Mahasen Saleh; Samira Rifai; Asim Belgaumi; Layla Osman; Khairy Ashraf; Mohammed Salim; Ameurfina Silo; George Roberts Journal: Ann Saudi Med Date: 2008 Jul-Aug Impact factor: 1.526
Authors: Abdullateef Mohammed Ahmed; Hassan Al-Trabolsi; Mohammed Bayoumy; Ibraheem Abosoudah; Fawwaz Yassin Journal: Asian Pac J Cancer Prev Date: 2019-11-01